Table 2 Baseline demographics and comorbidities
From: The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis
Newly diagnosed ATTRv Amyloidosis patients N = 141 | Matched controlsa N = 423 | p value | |
|---|---|---|---|
Age, year, mean (SD) | 62.5 (14.3) | 62.5 (14.2) | n/ad |
18–34, n (%) | 6 (4.3) | 18 (4.3) | |
35–54 | 27 (19.1) | 81 (19.1) | |
55–64 | 52 (36.9) | 156 (36.9) | |
65+ | 56 (39.7) | 168 (39.7) | |
Female, n (%) | 76 (53.9) | 228 (53.9) | n/ad |
Region, n (%) | |||
Midwest | 26 (18.4) | 78 (18.4) | n/ad |
Northeast | 47 (33.3) | 141 (33.3) | |
South | 55 (39.0) | 165 (39.0) | |
West | 13 (9.2) | 39 (9.2) | |
Insurance type, n (%)b | 0.087 | ||
PPO/POS | 99 (70.2) | 239 (56.5) | |
HMO/EPO | 8 (5.7) | 30 (7.1) | |
CDHP/HDHP | 14 (9.9) | 72 (17.0) | |
Comprehensive | 20 (14.2) | 80 (18.9) | |
Charlson comorbidity index, mean (SD) | 2.7 (3.0) | 1.1 (1.9) | < 0.001 |
Number of chronic conditions, mean (SD) | 5.1 (2.7) | 3.2 (2.3) | < 0.001 |
Health care provider, n (%) | 0.018 | ||
Primary care | 65 (46.1) | 230 (54.4) | |
Cardiologist | 5 (3.5) | 10 (2.4) | |
Dermatologist | 4 (2.8) | 16 (3.8) | |
Gastroenterologist | 6 (4.3) | 6 (1.4) | |
Neurologist | 6 (4.3) | 2 (0.5) | |
Rheumatologist | 5 (3.5) | 6 (1.4) | |
Otherc/unknown | 50 (35.5) | 153 (36.2) | |